Children’s Hospital of Philadelphia Joins as Sixth ZEVASKYN Treatment Center
Children’s Hospital of Philadelphia has been activated as the sixth Qualified Treatment Center for ZEVASKYN gene-modified cellular sheets. ZEVASKYN (prademagene zamikeracel) provides autologous cell sheet-based gene therapy for RDEB patients, expanding access on the U.S. east coast.
1. CHOP Activation as Sixth Qualified Treatment Center
Children’s Hospital of Philadelphia has been activated as the sixth Qualified Treatment Center for ZEVASKYN gene-modified cellular sheets, broadening treatment availability for recessive dystrophic epidermolysis bullosa on the U.S. east coast and supporting additional patient enrollment.
2. ZEVASKYN Therapy and Clinical Benefits
ZEVASKYN (prademagene zamikeracel) is the first autologous cell sheet-based gene therapy for RDEB wounds, incorporating the functional COL7A1 gene into patient skin cells ex vivo. A single surgical application has demonstrated clinically meaningful wound healing and pain reduction in adult and pediatric patients.
3. Commercial Strategy and Patient Support
Abeona is partnering with CHOP under leadership of Dr. Marissa Perman to deliver ZEVASKYN treatment, backed by its Abeona Assist program. This comprehensive support offers insurance navigation, financial assistance, travel logistics and ongoing monitoring to streamline therapy access and enhance patient outcomes.